



## **CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting**

February 27, 2019

ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of the CRISPR team will present two posters at the American Association for Cancer Research (AACR) Annual Meeting, held March 29 to April 3, 2019, at the Georgia World Congress Center in Atlanta, GA.

**Title:** Allogeneic CRISPR/Cas9 gene-edited CAR-T cells targeting CD33 show potent preclinical activity against AML cells (abstract #1428, poster)

**Time and Date:** Monday, April 1, 2019, from 8:00 a.m. to 12:00 p.m. ET

**Location:** Georgia World Congress Center, Exhibit Hall B, Poster Section 21

**Title:** Targeting multiple solid tumor types with anti-CD70 allogeneic CAR-T cells (abstract #3184, poster)

**Time and Date:** Tuesday, April 2, 2019, from 8:00 a.m. to 12:00 p.m. ET

**Location:** Georgia World Congress Center, Exhibit Hall B, Poster Section 22

### **About CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit [www.crisprtx.com](http://www.crisprtx.com).

### **CRISPR Investor Contact:**

Susan Kim

[susan.kim@crisprtx.com](mailto:susan.kim@crisprtx.com)

### **CRISPR Media Contact:**

Jennifer Paganelli

WCG on behalf of CRISPR

347-658-8290

[jpaganelli@wcgworld.com](mailto:jpaganelli@wcgworld.com)



Source: CRISPR Therapeutics AG